New Drug Approval News: FDA Approves Wilserdly Pill
People with advanced breast cancer that has stopped responding to hormone therapy have a new treatment option. The U.S. Food and Drug Administration has approved Wilserdly, a once-daily pill made by Roche, for use in combination with the cancer drug everolimus in adults whose tumours carry a specific genetic change that makes them resistant to standard hormone treatments. The approval, announced on Monday, November 16, is the first for a new class of oral breast cancer drug to show a clear advantage over existing therapy in a head-to-head trial, and it offers an all-pill alternative to the injections that many patients with advanced disease currently endure.
The new drug approval news covers a precisely defined group of patients: adults with estrogen receptor-positive, HER2-negative breast cancer that is locally advanced or has spread to other parts of the body, whose tumours carry a mutation in a gene called ESR1, and whose disease has come back or got worse despite earlier hormone therapy. That combination — the most common form of breast cancer, carrying a specific mutation — describes a large and growing population. Up to 40 percent of patients with hormone receptor-positive metastatic breast cancer develop ESR1 mutations over time, and those mutations are considered the primary cause of hormone therapy resistance. When they appear, the drugs that once held the cancer in check stop working, and patients and their doctors have had few good options.
Wilserdly, known generically as giredestrant, is designed to solve exactly that problem. It belongs to a new generation of drugs called oral selective estrogen receptor degraders, or SERDs, which work by binding to the estrogen receptor — the protein that drives the growth of these tumours — and destroying it, shutting down the signalling that fuels the cancer. Earlier SERDs had to be given by injection and were limited in their effectiveness; Wilserdly is a pill taken once a day, and it was designed to achieve deep and sustained inhibition of the estrogen receptor even when the receptor has been altered by an ESR1 mutation. Taken together with everolimus, a drug that blocks a second growth pathway, it offers a fully oral regimen for patients who have already been through several rounds of treatment.
The Trial Behind the Approval
The FDA's decision rests on the results of a phase III trial called evERA Breast Cancer, published in The New England Journal of Medicine, which compared Wilserdly plus everolimus against standard hormone therapy plus everolimus in patients whose cancer had advanced after earlier treatment. The trial enrolled 373 adults with ER-positive, HER2-negative breast cancer who had previously received a CDK4/6 inhibitor — the class of drugs that has become the standard first treatment for this type of cancer — together with hormone therapy. Of those 373 patients, 207 had tumours carrying ESR1 mutations, the group in which the new drug was expected to work best, and the group on which the FDA's approval is based.
The results in that group were striking. Patients who received Wilserdly plus everolimus went a median of 10 months before their cancer progressed, compared with 5.5 months for patients on standard therapy plus everolimus — nearly doubling the time the disease was held in check. The risk of disease progression or death was reduced by 62 percent, a hazard ratio of 0.38, a figure that in oncology is considered a large and clinically meaningful benefit. The confirmed response rate — the share of patients whose tumours shrank measurably — was 27 percent with Wilserdly, against 14 percent with standard therapy. Overall survival data were still immature at the time of the analysis, meaning not enough patients had died for a reliable comparison of how long the two groups lived, and the approval is therefore based on delaying progression rather than on a proven survival advantage.
The trial's design matters because it tested Wilserdly against a real alternative rather than against a placebo. Patients in the control group received a physician's choice of standard hormone therapy together with everolimus, the same backbone drug used in the Wilserdly arm, so the difference in outcomes can be attributed to the new pill itself. Roche described Wilserdly as the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination therapy in a post-CDK4/6 inhibitor setting in a head-to-head phase III trial — a careful formulation, but one that captures why the result has been welcomed by oncologists. Patients who have already been through CDK4/6 inhibitors and hormone therapy are among the hardest to treat, and until now there has been little evidence that any oral drug could do better than the existing options for them.
The regimen itself is straightforward: Wilserdly 30 milligrams once daily, with or without food, plus everolimus 10 milligrams once daily. The FDA also authorised a companion diagnostic test, Foundation Medicine's FoundationOne Liquid CDx, which detects ESR1 mutations in circulating tumour DNA from a blood sample, so that doctors can identify the patients whose tumours carry the mutation without needing a tissue biopsy. The test is the first ESR1 companion diagnostic for an oral estrogen receptor drug, and it is covered by Medicare for patients with advanced cancer. The approval was reviewed under the FDA's Project Orbis, an international programme that allows regulators in the United States, Canada and other countries to review cancer drugs together, and it involved Health Canada and Israel's Ministry of Health alongside the FDA.
A Bigger Decision Still to Come
The approval announced on Monday may be only the first of two decisions on Wilserdly this month. The FDA is also reviewing the drug as an adjuvant treatment — given after surgery, to reduce the risk of the cancer coming back — for adults with ER-positive, HER2-negative stage I, II and III breast cancer at intermediate to high risk of recurrence. That application, supported by the results of a second phase III trial called lidERA Breast Cancer, was accepted under the FDA's Priority Review programme, and the agency has set a decision date of November 30, 2026. If Wilserdly is approved in that setting as well, it would become the first SERD approved for both adjuvant and advanced ER-positive breast cancer — a much larger market, and a much bigger change in how the disease is treated.
The adjuvant decision is arguably the more consequential of the two. Most breast cancer is diagnosed early, when surgery can remove the tumour, and the question of what treatment to give afterwards to prevent recurrence affects far more patients than the advanced-disease setting. Hormone therapy after surgery is already the standard of care, and it works well for most patients; the challenge has been identifying the minority whose cancers are likely to return and giving them something stronger. The lidERA trial was designed to answer whether adding Wilserdly to standard therapy after surgery could reduce recurrence in that higher-risk group, and the FDA's decision later this month will determine whether the drug moves from a treatment for advanced disease into the much larger world of early breast cancer care.
The approval came four weeks ahead of the FDA's own goal date of December 18, a sign that the agency regarded the application as straightforward, and it arrived in a week when the FDA itself was in the news for other reasons. The White House withdrew its nominee to lead the agency, physician Heidi Overton, amid signs she lacked the votes for Senate confirmation, leaving the agency's leadership uncertain even as its scientists continued to clear new medicines. The contrast — a major drug approval on the same day the commissioner's nomination collapsed — was a reminder that the FDA's review work continues regardless of the politics surrounding it, and that the agency's drug evaluation teams operate on timelines set by law rather than by the news cycle.
What the Approval Means for Patients
For the patients the approval covers, the practical difference is significant. Advanced ER-positive, HER2-negative breast cancer is a chronic disease that many women live with for years, cycling through successive treatments as each one eventually stops working. The current options after hormone therapy and CDK4/6 inhibitors fail include chemotherapy, which is effective but comes with substantial side effects, and injectable hormone drugs such as fulvestrant, which require regular clinic visits for intramuscular injections. An oral regimen that can be taken at home, and that in a trial nearly doubled the time before the cancer progressed, is a meaningful improvement in both effectiveness and quality of life — particularly for patients who have already endured multiple rounds of treatment.
The benefit is not without limits, and doctors will be careful about who receives the drug. The approval is restricted to patients whose tumours carry an ESR1 mutation confirmed by an FDA-authorised test, which means that blood testing will become a routine part of the decision for patients whose cancer has progressed on hormone therapy. Not all patients will carry the mutation, and for those who do not, Wilserdly is not approved. The drug's side effects, as reported in the trial, were manageable but real, and the combination with everolimus — a drug known for causing mouth sores, rash and lung inflammation in some patients — will require monitoring. Overall survival data are not yet available, so the approval is a promise of more time before the disease worsens, not yet a proven promise of longer life. Those are the honest limits of the evidence, and they are the ones oncologists will weigh when deciding whether to prescribe it.
The commercial stakes are also substantial. Roche has six phase III trials of Wilserdly under way, including a study called pionERA that tests the drug against fulvestrant in combination with a CDK4/6 inhibitor, and the company is positioning the drug as a cornerstone of its breast cancer franchise. The market for ER-positive breast cancer drugs is one of the largest in oncology, and a drug that works after the current standard treatments fail has the potential to become a standard of care for a large population. Analysts have noted that the adjuvant decision due on November 30 will matter far more commercially than the advanced-disease approval, because it would open the drug to patients at an earlier stage of the disease, where treatment lasts longer and the eligible population is many times larger.
The Science of Resistance
To understand why Wilserdly matters, it helps to understand what goes wrong in the disease it treats. Estrogen receptor-positive breast cancer is driven by estrogen, which binds to receptors on the tumour cells and signals them to grow. Hormone therapies work by blocking that signal, either by stopping the body from making estrogen or by blocking the receptor itself. For many patients, these drugs work for years. But cancer evolves, and in up to 40 percent of patients with advanced disease, the tumour develops a mutation in the ESR1 gene — the gene that codes for the estrogen receptor itself. The mutated receptor no longer needs estrogen to switch on; it stays active on its own, and the hormone therapies that worked before become useless. That is the moment when patients run out of good options, and it is the moment Wilserdly is designed for.
The new generation of oral SERDs, of which Wilserdly is the first to win FDA approval in this setting, was designed specifically to overcome that problem. By binding to the mutated receptor and marking it for destruction, the drug removes the very protein that is driving the cancer's growth, rather than merely trying to block it. The approach has been a decade in the making, with several earlier candidates failing in trials before reaching the market. Wilserdly's success in the evERA trial — a 62 percent reduction in the risk of progression or death in the ESR1-mutated group — is the first clear demonstration that the approach works in patients whose cancers have already become resistant to hormone therapy, and it validates a line of research that many in the field had begun to doubt.
The approval also reflects a broader shift in cancer drug development toward precision medicine — treatments matched to the genetic features of a patient's tumour rather than to the organ where the cancer started. The requirement for an FDA-authorised test to confirm the ESR1 mutation before prescribing Wilserdly is part of that shift, and the authorisation of a blood-based test that detects the mutation in circulating tumour DNA is a sign of how far the technology has come. A decade ago, identifying a mutation like ESR1 required a tissue biopsy; today it can be done from a blood draw. That makes it practical to test every patient whose cancer progresses, and to match each one to the drug most likely to work for them.
What Happens Next
The next milestone is the FDA's decision on the adjuvant application, due by November 30. If that decision is positive, Wilserdly will move from a drug for advanced disease into the treatment of early breast cancer, and the number of patients eligible for it will grow dramatically. Roche's other trials, including pionERA, will report in the coming years and will determine whether the drug can move earlier still in the sequence of treatments, potentially displacing older hormone therapies for newly diagnosed patients. For now, the approval gives doctors a new option for a group of patients who had few, and it gives patients whose cancers carry the ESR1 mutation a reason for cautious optimism — a pill, taken at home, that in a rigorous trial held the disease at bay for nearly twice as long as the standard alternative.
That is the measure of what the FDA approved on Monday: not a cure, and not yet a proven extension of life, but a real and measurable improvement for people facing one of the hardest moments in cancer care — the moment when the treatment that has been working stops working, and the question becomes what comes next. For the first time, for a defined group of patients, the answer is a pill.
Source: U.S. Food and Drug Administration